Uveal Melanoma: all 281 studies

Page 2 of 3. Open to participants first (50), then studies with results posted, then the rest; newest registration first within each.

• Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye MelanomaTerminatedNCT00482911Phase 2Results posted
• VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00450255Phase 2Results posted
• Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerCompletedNCT00445965Phase 2Results posted
• Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV MelanomaCompletedNCT00398073Phase 1Results posted
• Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the EyeCompletedNCT00329641Phase 2Results posted
• Melanoma Vaccine With Peptides and LeuprolideCompletedNCT00254397Phase 2Results posted
• AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaCompletedNCT00243061Phase 2Results posted
• Vorinostat in Treating Patients With Metastatic or Unresectable MelanomaCompletedNCT00121225Phase 2Results posted
• Lenalidomide (Revlimid) to Treat Advanced Ocular MelanomaCompletedNCT00109005Phase 2Results posted
• Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV MelanomaCompletedNCT00084656Phase 2Results posted
• Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With TebentafuspWithdrawnNCT07803562Phase 2
• Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) SubjectsActive, not recruitingNCT07421739
• A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic MelanomaTerminatedNCT07076550Phase 1
• Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous MelanomaActive, not recruitingNCT06863870
• iSITE: Investigation of Somatic Alterations in Tumours of the EyeCompletedNCT06861647
• Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaActive, not recruitingNCT06784648Phase 1/2
• A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal MelanomaActive, not recruitingNCT06717126Phase 2
• Eye Plaque Brachytherapy for Ocular MelanomaActive, not recruitingNCT06432660
• Psychoeducation for Uveal MelanomaActive, not recruitingNCT06075589Not applicable
• A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal MelanomaActive, not recruitingNCT06007690Phase 3
• IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaActive, not recruitingNCT05987332Phase 2/3
• (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaActive, not recruitingNCT05907954Phase 2
• A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid TumorsActive, not recruitingNCT05812027
• Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal MelanomaWithdrawnNCT05677373Phase 1/2
• Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory MelanomaCompletedNCT05628883Phase 1
• A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid TumorsTerminatedNCT05576077Phase 1
• Olaparib in Combination With Pembrolizumab for Advanced Uveal MelanomaActive, not recruitingNCT05524935Phase 2
• Targeted Alpha Particle Radiotherapy for Metastatic Uveal MelanomaActive, not recruitingNCT05496686Phase 1
• Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2WithdrawnNCT05482074Phase 2
• A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant MelanomasActive, not recruitingNCT05415072Phase 1/2
• Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma PatientsActive, not recruitingNCT05377957
• Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain MetastasesTerminatedNCT05341349Phase 1
• Tebentafusp in Molecular Relapsed Disease (MRD) MelanomaActive, not recruitingNCT05315258Phase 2
• Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)CompletedNCT05282901Phase 2
• Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)TerminatedNCT05266430
• A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsCompletedNCT05199584Phase 2
• Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular MelanomaCompletedNCT05187884Phase 2
• The Role of Genetic Mutations and of Circulating mRNAs in Uveal MelanomaStatus unknownNCT05179174
• Binimetinib Plus Belinostat for Subjects With Metastatic Uveal MelanomaActive, not recruitingNCT05170334Phase 2
• Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)CompletedNCT05169957Phase 1
• Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsTerminatedNCT05075993Phase 1
• Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal MelanomaStatus unknownNCT05047276Phase 1/2
• An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular MelanomaActive, not recruitingNCT05022901Phase 3
• Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal MelanomaCompletedNCT05004025Phase 1
• Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal MelanomaTerminatedNCT04935229Phase 1
• Targeted Imaging of Melanoma for Alpha-Particle RadiotherapyCompletedNCT04904120Phase 1
• FHD-286 in Subjects With Metastatic Uveal MelanomaTerminatedNCT04879017Phase 1
• Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver MetastasesCompletedNCT04812470Phase 1
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver MetastasesActive, not recruitingNCT04728633Phase 2
• Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)CompletedNCT04728113Not applicable
• Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving ImmunotherapyActive, not recruitingNCT04645680Phase 2
• A Prospective Natural History Study in Uveal MelanomaActive, not recruitingNCT04588662
• Uveal Melanoma and Brachytheraphy: Long-term Outcomes.CompletedNCT04577742
• A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive MelanomasCompletedNCT04551352Phase 1
• Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesCompletedNCT04463368Phase 1
• Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal MelanomaCompletedNCT04417530Phase 2
• Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)CompletedNCT04364230Phase 1/2
• Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsActive, not recruitingNCT04336241Phase 1
• A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersActive, not recruitingNCT04328844Phase 1
• PHP and Immunotherapy in Metastasized UMActive, not recruitingNCT04283890Phase 1/2
• Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal MelanomaWithdrawnNCT04184518Phase 2
• Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabActive, not recruitingNCT04130516Phase 1/2
• Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)CompletedNCT04118062Not applicable
• Dexamethasone Implant for Retinal Detachment in Uveal MelanomaCompletedNCT04082962Phase 1
• Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)Status unknownNCT04025424
• Study of the Activity of PD-1 Inhibitors in Metastatic Uveal MelanomaCompletedNCT03964298
• A Registry of Subjects With Primary Indeterminate Lesions or Choroidal MelanomaActive, not recruitingNCT03941379
• Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal MelanomaCompletedNCT03922880Phase 1
• Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV MelanomaTerminatedNCT03865212Phase 1
• A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedNCT03746431Phase 1
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
• C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)Active, not recruitingNCT03635632Phase 1
• A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsActive, not recruitingNCT03611868Phase 1/2
• Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular MelanomaActive, not recruitingNCT03528408Phase 2
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal MelanomaActive, not recruitingNCT03467516Phase 2
• CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)CompletedNCT03408587Phase 1
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• A Study of PLX2853 in Advanced Malignancies.CompletedNCT03297424Phase 1
• Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal MelanomaCompletedNCT03172299Phase 3
• Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaActive, not recruitingNCT03068624Phase 1
• Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal DiseaseActive, not recruitingNCT03025256Phase 1
• Vorinostat in Patients With Class 2 High Risk Uveal MelanomaWithdrawnNCT03022565Early Phase 1
• Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver MetastasisCompletedNCT02936388Phase 2
• Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesStatus unknownNCT02913417Phase 1/2
• The Role of Inflammation in Ocular TumoursStatus unknownNCT02909517
• Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)CompletedNCT02875652Not applicable
• Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)CompletedNCT02874040Not applicable
• Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)CompletedNCT02849145Not applicable
• Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal MelanomaCompletedNCT02843386Phase 3
• Intermittent Selumetinib for Uveal MelanomaCompletedNCT02768766Phase 1
• Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the EyeCompletedNCT02697630Phase 2
• Study With T-cel Receptor Gene Therapy in Metastatic MelanomaStatus unknownNCT02654821Phase 1/2
• Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaCompletedNCT02626962Phase 2
• Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal MelanomasTerminatedNCT02602756Not applicable
• A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.TerminatedNCT02601378Phase 1
• Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic DisseminationCompletedNCT02517736Phase 2
• TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam TherapyStatus unknownNCT02379000Phase 4
• 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient OutcomesCompletedNCT02376920
• Trial of AEB071 in Combination With BYL719 in Patients With MelanomaCompletedNCT02273219Phase 1

← Uveal Melanoma overview